[ ]
Кобицистат (Cobicistat)
Международное непатентованное наименование Кобицистат (Cobicistat)
Торговое наименование Tybost
Производитель, страна Gilead Sciences, USA
Механизм действия

Cobicistat inhibits the human CYP3A proteins, which are known to degrade important antiretroviral molecules. Cobicistat is thus importantly used in combination with other drugs to help enhance their efficacy.


Cobicistat is effectively eliminate the anti-HIV activity of ritonavir while preserving its inhibitory effects on the CYP3A isozyme family of proteins. Cobicistat is therefore able to increase plasma concentration of other coadministered anti-HIV drugs without the risk of causing cobicistat-resistant mutations in the HIV virus.


FDA-approved since 2015, approved to treat HIV-1 infection.

Публикации COVID-19

Valentina SpezzaniAlessio PiunnoHans-Ulrich Iselin. Benign COVID-19 in an Immunocompromised Cancer Patient - The Case of a Married Couple. Swiss Med Wkly. 2020 Apr 11;150:w20246. DOI: 10.4414/smw.2020.20246.

Клинические исследования
Название протокола A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)
Дата начала и окончания КИ February 1, 2020 - December 31, 2020
Название организации, проводящей КИ Zhongnan Hospital of Wuhan University
Страны China
Фаза -
Кол-во пациентов 100
Название протокола Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
Дата начала и окончания КИ January 30, 2020 - December 31, 2020
Название организации, проводящей КИ Shanghai Public Health Clinical Center
Страны China
Фаза III
Кол-во пациентов 30